Form 4: Chemed CEO McNamara sells 1,500 shares

Chemed Corp CEO and director Kevin J. McNamara sold 1,500 shares at a $369.37 weighted average on March 27, 2026, and now holds 92,219 shares directly.

Summary

• Kevin J. McNamara, Chemed Corp’s president, CEO, and director, sold 1,500 shares of capital stock on 03/27/2026 (transaction code S).
• Weighted average sale price was $369.37 per share, with trade prices ranging from $365.76 to $373.24.
• Post-transaction direct beneficial ownership stands at 92,219 shares.
• Approximate gross proceeds from the sale were $554,055 (1,500 x $369.37).
• The Form 4 was signed on 03/30/2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral: a modest insider sale with continued significant ownership and no operational disclosures.

Positives

• McNamara maintains a substantial direct beneficial stake of 92,219 shares after the sale.
• Sale prices were within a tight market range ($365.76–$373.24) with a $369.37 weighted average, indicating orderly execution.
• Filing timing (03/30/2026) aligns with the SEC’s two-business-day reporting requirement.

Negatives

• Insider sale by the president, CEO, and director of 1,500 shares on 03/27/2026 for approximately $554,055.
• Direct ownership decreased by 1,500 shares (about 1.6% of pre-transaction holdings, from 93,719 to 92,219).

Future Outlook

NA

Management Comments

• The reported price is a weighted average; shares were sold in multiple transactions between $365.76 and $373.24. Full details by price increment will be provided to the company, shareholders, or SEC staff upon request.

Industry Context

StockSavvy.ai notes that insider sales occur routinely across healthcare services and broader markets for diversification and liquidity and do not inherently indicate a change in fundamentals. The transaction size is modest relative to typical large-cap executive holdings and does not alter industry positioning for Chemed.

Comparison to Industry Standards

• Not applicable: This insider transaction filing does not include operating or financial performance metrics to benchmark against peers such as HCA Healthcare, DaVita, or UnitedHealth Group.

Stakeholder Impact

• Slight increase in market float from the sale of 1,500 shares.
• Continued alignment of CEO incentives with shareholders through remaining 92,219-share direct stake.

Key Dates

Recommendation

A routine, small-scale insider sale by the CEO does not change the investment thesis or indicate operational shifts; maintain a hold pending fundamental updates.

Keywords

Chemed, CHE, insider sale, Form 4, Kevin J. McNamara, beneficial ownership, capital stock, Section 16 filing, weighted average price, insider trading disclosure